GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (FRA:3O61) » Definitions » Shiller PE Ratio

Cascadian Therapeutics (FRA:3O61) Shiller PE Ratio : (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is Cascadian Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cascadian Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Cascadian Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cascadian Therapeutics Shiller PE Ratio Chart

Cascadian Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cascadian Therapeutics Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cascadian Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Cascadian Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cascadian Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cascadian Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cascadian Therapeutics's Shiller PE Ratio falls into.



Cascadian Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cascadian Therapeutics's E10 for the quarter that ended in Dec. 2017 is calculated as:

For example, Cascadian Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2017 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2017 (Change)*Current CPI (Dec. 2017)
=-0.287/104.0111*104.0111
=-0.287

Current CPI (Dec. 2017) = 104.0111.

Cascadian Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200803 -1.001 90.090 -1.156
200806 -0.965 92.320 -1.087
200809 -0.753 92.307 -0.848
200812 4.795 88.697 5.623
200903 -0.597 89.744 -0.692
200906 -1.285 91.003 -1.469
200909 -0.988 91.120 -1.128
200912 -0.329 91.111 -0.376
201003 -0.133 91.821 -0.151
201006 -0.834 91.962 -0.943
201009 -0.778 92.162 -0.878
201012 -1.588 92.474 -1.786
201103 -1.027 94.283 -1.133
201106 -3.789 95.235 -4.138
201109 -0.654 95.727 -0.711
201112 -1.231 95.213 -1.345
201203 0.954 96.783 1.025
201206 -0.717 96.819 -0.770
201209 -0.698 97.633 -0.744
201212 -0.549 96.871 -0.589
201303 -0.648 98.209 -0.686
201306 -1.273 98.518 -1.344
201309 -0.539 98.790 -0.567
201312 -0.350 98.326 -0.370
201403 -0.607 99.695 -0.633
201406 -0.397 100.560 -0.411
201409 -0.419 100.428 -0.434
201412 -1.622 99.070 -1.703
201503 -0.444 99.621 -0.464
201506 -0.588 100.684 -0.607
201509 -0.267 100.392 -0.277
201512 -0.532 99.792 -0.554
201603 -0.727 100.470 -0.753
201606 -1.397 101.688 -1.429
201609 -0.463 101.861 -0.473
201612 -0.370 101.863 -0.378
201703 -0.280 102.862 -0.283
201706 -0.267 103.349 -0.269
201709 -0.235 104.136 -0.235
201712 -0.287 104.011 -0.287

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cascadian Therapeutics  (FRA:3O61) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cascadian Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cascadian Therapeutics (FRA:3O61) Business Description

Traded in Other Exchanges
N/A
Address
Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.

Cascadian Therapeutics (FRA:3O61) Headlines

No Headlines